Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB25FYX30
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,137
Award facts
- Contract value 100% obligated
- $49,137.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $49,137.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. This firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of September 5, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its robust portfolio of contracts with the Defense Logistics Agency, specializing in the distribution of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's federal contracting experience encompasses oncology treatments, immunotherapies, vaccines, and specialty medications, positioning it as a reliable vendor for supporting the medical supply needs of military health facilities. This delivery order for Keytruda, an oncology immunotherapy, exemplifies the company's role in providing advanced pharmaceutical products directly to the federal healthcare system.
Quick answers
Who was awarded contract SPE2DB25FYX30?
SPE2DB25FYX30 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 14, 2025.
How much is contract SPE2DB25FYX30 worth?
The government has obligated $49,137 on SPE2DB25FYX30.
Is contract SPE2DB25FYX30 an order under another contract?
Yes. SPE2DB25FYX30 is a delivery order under SPE2DB22D9133, an indefinite delivery contract.
Was contract SPE2DB25FYX30 competed?
The extent of competition for SPE2DB25FYX30 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award